Vemircopan
- Generic Name
- Vemircopan
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28BrN7O3
- CAS Number
- 2086178-00-7
- Unique Ingredient Identifier
- HN6I4K50QB
AstraZeneca Discontinues Two Alexion Rare Disease Programs Amid Strong Q4 Performance
• AstraZeneca has terminated the development of two Alexion-acquired assets - vemircopan for rare liver and kidney conditions and ALXN1910 for bone metabolism disorders - due to insufficient efficacy data.
• The company's rare disease portfolio showed robust growth with Q4 2024 revenue reaching $2.4 billion, driven by Ultomiris which generated nearly $1.1 billion, representing a 33% increase.
• Despite the setbacks, AstraZeneca reported strong Q4 earnings of $14.90 billion, exceeding analyst expectations, with significant contributions from its oncology portfolio and rare disease treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath